* 总部位于新加坡的微小核糖核酸（miRNA）技术公司--Mirxes2629.HK周五香港首日挂牌，盘初较招股价飙涨37%，触及31.95港元。
* 该公司按招股价每股23.3港元发售4,662万股股份，集资10.86亿港元，上市市值64亿港元；香港公开发售和国际配售分别获25.5倍及0.98倍认购。
基石投资者--北京浔瑞以及复星国际0656.HK旗下Evergreen Gate分别占上市后股本6.03%及0.95%股份。
* 该公司的核心产品GASTROClearTM为一个由12种miRNA生物标志物组成的用于胃癌筛查的基于血液的miRNA检测组。
* 香港股市恒生指数.HSI盘初跌0.1%，恒生香港上市生物科技指数.HSHKBIO涨1.8%。（完）
更多股市简讯请点选CN-CMN-HOT
(记者 雷美珍；审校 杨淑祯)
((alison.lui@thomsonreuters.com; +852 3462 7749;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.